|
|
Other links at Articles > Family Medicine |
| 4. |
Alemtuzumab More Effective Than Interferon Beta-1a, but Serious Safety Concerns Remain
|
|
|
Alemtuzumab is more effective than interferon beta-1a for the treatment of early relapsing–remitting multiple sclerosis, reducing relapse and disability rates and restoring lost function. However, the monoclonal antibody is associated with serious safety concerns, including autoimmunity, which manifested as immune thrombocytopenic purpura in 3 patients, 1 of whom died. Medscape Medical News
|
| 5. |
Grief -- When to Treat It
|
|
|
Sid Zisook, MD, of UCSD talks about grief, how it is often misunderstood, and when treatment may be necessary. University of California, San Diego, School of Medicine
|
|
|
